Total Payments
$3,776
2024 Payments
$240.43
Companies
33
Transactions
141
Medicare Patients
5,762
Medicare Billing
$225,073
Payment Breakdown by Category
Food & Beverage$2,198 (58.2%)
Research$1,578 (41.8%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $2,198 | 138 | 58.2% |
| Unspecified | $1,578 | 3 | 41.8% |
Payments by Type
General
$2,198
138 transactions
Research
$1,578
3 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $1,578 | 3 | $0 (2017) |
| Novo Nordisk Inc | $328.29 | 26 | $0 (2024) |
| ABBVIE INC. | $302.04 | 11 | $0 (2023) |
| GlaxoSmithKline, LLC. | $219.70 | 19 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $173.72 | 7 | $0 (2024) |
| Allergan, Inc. | $166.11 | 8 | $0 (2020) |
| PFIZER INC. | $139.28 | 9 | $0 (2024) |
| Lilly USA, LLC | $112.85 | 7 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $105.90 | 7 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $65.23 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $240.43 | 14 | Novo Nordisk Inc ($100.39) |
| 2023 | $340.52 | 20 | ABBVIE INC. ($51.91) |
| 2022 | $478.49 | 32 | Novo Nordisk Inc ($143.64) |
| 2021 | $142.91 | 6 | AbbVie Inc. ($106.96) |
| 2020 | $192.92 | 11 | Allergan, Inc. ($146.24) |
| 2019 | $226.34 | 17 | Novo Nordisk Inc ($38.75) |
| 2018 | $131.35 | 8 | Boehringer Ingelheim Pharmaceuticals, Inc. ($51.47) |
| 2017 | $2,023 | 33 | Eli Lilly and Company ($1,578) |
All Payment Transactions
141 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: Diabetes | ||||||
| 12/11/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: Neuropsychiatry | ||||||
| 12/04/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.74 | General |
| Category: Diabetes | ||||||
| 11/26/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Diabetes | ||||||
| 11/19/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $20.53 | General |
| Category: RESPIRATORY | ||||||
| 11/12/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.85 | General |
| Category: Inflammation | ||||||
| 11/04/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.77 | General |
| Category: Diabetes | ||||||
| 10/27/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.35 | General |
| Category: Diabetes | ||||||
| 10/01/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: RESPIRATORY | ||||||
| 04/29/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $16.13 | General |
| Category: Diabetes | ||||||
| 03/19/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $17.50 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 03/12/2024 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $13.16 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 03/05/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $17.41 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/07/2024 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $17.02 | General |
| Category: Diabetes | ||||||
| 12/19/2023 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $11.80 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 11/28/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $15.46 | General |
| Category: DIABETES | ||||||
| 10/23/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: Diabetes | ||||||
| 10/12/2023 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/06/2023 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $24.78 | General |
| Category: Biological | ||||||
| 09/27/2023 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.20 | General |
| Category: Diabetes | ||||||
| 09/26/2023 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $11.74 | General |
| Category: CNS Stimulant for ADHD | ||||||
| 09/19/2023 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/31/2023 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: Endocrinology | ||||||
| 08/16/2023 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $13.15 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/03/2023 | Corium, LLC | Azstarys (Drug) | Food and Beverage | In-kind items and services | $11.12 | General |
| Category: CNS Stimulant for ADHD | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER STUDY WITH A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED MAINTENANCE DOSING PERIOD AND A LONG TERM EXTENSION PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF LY2439821 IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $659.70 | 1 |
| A PHASE 2, MULTICENTER, RANDOMIZED, PARALLEL-ARM, PLACEBO- CONTROLLED STUDY OF LY3074828 IN SUBJECTS WITH MODERATE-TO- SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $556.80 | 1 |
| MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $361.10 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 20 | 899 | 1,261 | $107,653 | $44,556 |
| 2022 | 21 | 1,403 | 1,873 | $143,496 | $51,921 |
| 2021 | 27 | 1,762 | 2,661 | $194,517 | $75,123 |
| 2020 | 27 | 1,698 | 2,491 | $163,108 | $53,473 |
Total Patients
5,762
Total Services
8,286
Medicare Billing
$225,073
Procedure Codes
95
All Medicare Procedures & Services
95 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 120 | 238 | $43,970 | $17,949 | 40.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 97 | 126 | $16,114 | $6,222 | 38.6% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2023 | 14 | 14 | $4,900 | $3,668 | 74.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 43 | 44 | $3,510 | $3,158 | 90.0% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 12 | 15 | $3,355 | $2,202 | 65.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 17 | 17 | $2,231 | $2,151 | 96.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 99 | 200 | $1,889 | $1,670 | 88.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 44 | 45 | $1,530 | $1,328 | 86.8% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 78 | 92 | $6,357 | $1,168 | 18.4% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 85 | 111 | $6,285 | $1,128 | 18.0% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 18 | 18 | $4,172 | $667.08 | 16.0% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 72 | 85 | $2,720 | $639.24 | 23.5% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 32 | 59 | $3,102 | $552.16 | 17.8% |
| 80048 | Blood test, basic group of blood chemicals (calcium, total) | Office | 2023 | 35 | 52 | $2,730 | $431.08 | 15.8% |
| 84443 | Blood test, thyroid stimulating hormone (tsh) | Office | 2023 | 20 | 26 | $1,820 | $427.96 | 23.5% |
| 87084 | Screening test for pathogenic organisms with colony count | Office | 2023 | 14 | 15 | $675.00 | $397.95 | 59.0% |
| G0009 | Administration of pneumococcal vaccine | Office | 2023 | 14 | 14 | $476.00 | $383.63 | 80.6% |
| 82043 | Urine microalbumin (protein) level | Office | 2023 | 35 | 36 | $828.00 | $198.10 | 23.9% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 35 | 36 | $720.00 | $177.80 | 24.7% |
| 81003 | Automated urinalysis test | Office | 2023 | 15 | 18 | $270.00 | $37.40 | 13.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 217 | 394 | $70,769 | $28,952 | 40.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 108 | 125 | $15,259 | $6,700 | 43.9% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 51 | 51 | $3,818 | $3,492 | 91.5% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2022 | 137 | 162 | $11,194 | $2,127 | 19.0% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2022 | 151 | 191 | $10,814 | $1,980 | 18.3% |
About Dr. Jonathan Harris, MD
Dr. Jonathan Harris, MD is a Family Medicine healthcare provider based in Endwell, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1376563551.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jonathan Harris, MD has received a total of $3,776 in payments from pharmaceutical and medical device companies, with $240.43 received in 2024. These payments were reported across 141 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($2,198).
As a Medicare-enrolled provider, Harris has provided services to 5,762 Medicare beneficiaries, totaling 8,286 services with total Medicare billing of $225,073. Data is available for 4 years (2020–2023), covering 95 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Endwell, NY
- Active Since 07/20/2006
- Last Updated 07/08/2007
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1376563551
Products in Payments
- TALTZ (Drug) $1,021
- UBRELVY (Drug) $358.85
- ENTRESTO (Drug) $160.60
- JARDIANCE (Drug) $155.89
- ELIQUIS (Drug) $119.71
- Ozempic (Drug) $116.17
- Rybelsus (Drug) $92.19
- VRAYLAR (Drug) $89.43
- Saxenda (Drug) $75.40
- TRINTELLIX (Drug) $65.23
- FreeStyle Libre (Device) $48.62
- BASAGLAR (Drug) $48.13
- SHINGRIX (Biological) $48.10
- Azstarys (Drug) $45.66
- AREXVY (Drug) $39.00
- BREO (Drug) $38.18
- VESICARE (Drug) $33.62
- Korlym (Drug) $31.59
- FARXIGA (Drug) $31.40
- Carto 3 System (Device) $31.34
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Endwell
Suchet Patel, Md, MD
Family Medicine — Payments: $237,874
Family Medicine $237,874
Duncan Sze-Tu, Md, MD
Family Medicine — Payments: $15,417
Family Medicine $15,417
Eric Lorraine, Do, DO
Family Medicine — Payments: $12,555
Family Medicine $12,555
John Perry, Md, MD
Family Medicine — Payments: $6,123
Family Medicine $6,123
Kimberly Desantis, Md, MD
Family Medicine — Payments: $5,032
Family Medicine $5,032
Dr. Demetrios Gasparis, M.d, M.D
Family Medicine — Payments: $3,992
Family Medicine $3,992